Business Standard

Thursday, January 09, 2025 | 09:00 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Lupin gets inspection closure report from USFDA for Pithampur plant

Lupin Managing Director Nilesh Gupta, said the company has received the EIR for the plant with Voluntary Action Indicated (VAI) status

Lupin, Boehringer Ingelheim ink $700-mn deal for anti-cancer drug
Premium

The USFDA issues an EIR to a company when an inspection is satisfactorily closed.

BS Web TeamAgencies New Delhi
The US Food and Drug Administration (USFDA) has closed its inspection of Lupin's manufacturing facility in Pithampur, Madhya Pradesh, the company said on Thursday. The inspection for the facility was conducted by the US health regulator between February 3 and February 11, 2020, and concluded with two observations, the Mumbai-based company said.

The company has received the establishment inspection report (EIR) from USFDA for its Pithampur Unit-1 facility, Lupin said.

The USFDA issues an EIR to a company when an inspection is satisfactorily closed.

Lupin Managing Director Nilesh Gupta, said the company has received the EIR for the plant with
Topics : Lupin USFDA

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in